Opportunities to optimise direct‐acting oral anticoagulants
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1874
Abstract: The newer direct‐acting oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban – offer many advantages over older anticoagulants such as warfarin. However, in order to optimise their benefits, it is important that patients taking them… read more here.
Keywords: acting oral; oral anticoagulants; direct acting; opportunities optimise ... See more keywords